Media stories about Hutchison China MediTech (NASDAQ:HCM) have been trending somewhat positive on Thursday, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Hutchison China MediTech earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.6826607021951 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Shares of Hutchison China MediTech (HCM) traded down $1.38 during trading hours on Thursday, reaching $38.82. 92,400 shares of the company were exchanged, compared to its average volume of 113,543. Hutchison China MediTech has a 1 year low of $12.62 and a 1 year high of $42.25. The company has a quick ratio of 1.73, a current ratio of 1.84 and a debt-to-equity ratio of 0.09.
HCM has been the topic of several research analyst reports. BidaskClub raised Hutchison China MediTech from a “hold” rating to a “buy” rating in a research note on Saturday, December 30th. Canaccord Genuity upped their price objective on Hutchison China MediTech to $38.00 and gave the stock a “buy” rating in a report on Monday, October 16th.
TRADEMARK VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/11/hutchison-china-meditech-hcm-receives-media-impact-rating-of-0-13.html.
Hutchison China MediTech Company Profile
Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.
Receive News & Ratings for Hutchison China MediTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech and related companies with MarketBeat.com's FREE daily email newsletter.